


Invasion Transformation Resulting From Podocalyxin Knockdown

Tate Goodman
For: CAPS 200

4T1-Podo KD 3603



Invasion

- Inhibition of one invasion 'mode' often causes a transition to a new 'mode'^{1,2,10}.
- Single-cell invasion modes are amoeboid or mesenchymal¹.
- Amoeboid invasion is dependent on Rho/ROCK based contractility^{1,5,6}.
- Mesenchymal invasion displays upregulated vimentin and N-cadherin, invading independent of Rho/ROCK pathways^{1,6}.
- Over expression of podocalyxin drives collective cell invasion^{2,7}.

Podocalyxin

- Podocalyxin is linked to Ezrin and NHERF.
- Podocalyxin activates RhoA^{3,8}.
- Podocalyxin expression contributes invadopodia in mesenchymal invasion⁴.
- Knockdown/blocking podocalyxin blocks collective invasion through the ECM^{2,7}.
- 4T1 podocalyxin knockdown cells transitioned to single-cell invasion².




Image taken from: <http://jasn.asnjournals.org/content/15/9/2289/F9.expansion>⁸

Question & Hypothesis

- How do cells invade when invasion driver podocalyxin is inhibited to block collective invasion.
- If podocalyxin is knocked down in collectively invasive cancer cell lines, EMT will be initiated as a result of decreased activated RhoA.

Specific Aims

- Classify mode of invasion.
- Determine universality.
- Find out if this is specific to knockdowns.
- Look into invasion pathways.

Classifying Invasion

- Amoeboid
 - Block ROCK1 with Y-27632 in 4T1 podocalyxin knockdown cells.
 - Observe invasion through phase contrast videos, comparing against 4T1 podocalyxin knockdown cells.
- Mesenchymal Invasion
 - Fix and stain cells for vimentin, N-cadherin and actin using confocal microscopy.

Universality & Mechanism

- Universality:
 - Knockdown podocalyxin using shRNA in MiaPaca and HT29 cells.
 - Observe invasion in 3D through phase contrast.
 - Knockout podocalyxin in 4T1, imaging in phase contrast.
- Mechanism:
 - RNA-seq looking for, SNAIL1, SNAIL2/SLUG or TWIST1⁹, comparing against standard 4T1 cells.
 - Active RhoA assay, comparing concentrations in 4T1 and 4T1 podo KD cells.

Expected Outcomes

- Inhibition of ROCK will have minor to no effect.
- 4T1 podocalyxin knockdown cells will invade through EMT.
- Mia PaCa, HT29 cells will display similar single-cell invasion modes.
- 4T1 podo knockout cells will display decreased single-cell invasion capacity.
- Decreased active RhoA may cause EMT.

Significance

- Podocalyxin is a clinically significant target.
- Metastasis causes majority of cancer deaths.
- Podocalyxin therapy will be ineffective if another mode of invasion is activated.
- Future directions:
 - Will single-cell invasion be initiated in vivo?
 - Mechanism of action of the transformation.
 - Can this transformation be blocked?

References

1. Paňková, K., Rösel, D., Novotný, M. & Brábek, J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. *Cell. Mol. Life Sci.* 67, 63-71 (2009).
2. Graves, M. et al. The cell surface mucin podocalyxin regulates collective breast tumor budding. *Breast Cancer Research* 18, (2016).
3. Fukasawa, H. et al. Phosphorylation of Podocalyxin (Ser415) Prevents RhoA and Ezrin Activation and Disrupts Its Interaction with the Actin Cytoskeleton. *The American Journal of Pathology* 179, 2254-2265 (2011).
4. Lin, C. et al. Podocalyxin-like 1 promotes invadopodia formation and metastasis through activation of Rac1/Cdc42/cortactin signaling in breast cancer cells. *Carcinogenesis* 35, 2425-2435 (2014).
5. Kosla, J. et al. Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling. *Cell Communication and Signaling* 11, 51 (2013).
6. Sahai, E. & Marshall, C. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. *Nature Cell Biology* 5, 711-719 (2003).
7. Snyder, K. et al. Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. *Breast Cancer Research* 17, (2015).
8. Schmieder, S. Podocalyxin Activates RhoA and Induces Actin Reorganization through NHERF1 and Ezrin in MDCK Cells. *Journal of the American Society of Nephrology* 15, 2289-2298 (2004).
9. *Oncogenomics and Cancer Proteomics - Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer.* (InTech, 2013).
10. Wolf, K. et al. Compensation mechanism in tumor cell migration. *J Cell Biol* 160, 267-277 (2003).